6 results on '"Matheson, Nicholas J"'
Search Results
2. Efficacy of FFP3 respirators for prevention of SARS-CoV-2 infection in healthcare workers.
- Author
-
Ferris, Mark, Ferris, Rebecca, Workman, Chris, O'Connor, Eoin, Enoch, David A., Goldesgeyme, Emma, Quinnell, Natalie, Patel, Parth, Wright, Jo, Martell, Geraldine, Moody, Christine, Shaw, Ashley, Illingworth, Christopher J. R., Matheson, Nicholas J., and Weekes, Michael P.
- Subjects
- *
MEDICAL personnel , *COVID-19 , *PANDEMICS , *RESPIRATORY protective devices , *COVID-19 pandemic , *INFECTION prevention , *MEDICAL masks - Abstract
Background: Respiratory protective equipment recommended in the UK for healthcare workers (HCWs) caring for patients with COVID-19 comprises a fluid-resistant surgical mask (FRSM), except in the context of aerosol generating procedures (AGPs). We previously demonstrated frequent pauci- and asymptomatic severe acute respiratory syndrome coronavirus 2 infection HCWs during the first wave of the COVID-19 pandemic in the UK, using a comprehensive PCR-based HCW screening programme (Rivett et al., 2020; Jones et al., 2020). Methods: Here, we use observational data and mathematical modelling to analyse infection rates amongst HCWs working on 'red' (coronavirus disease 2019, COVID-19) and 'green' (non-COVID-19) wards during the second wave of the pandemic, before and after the substitution of filtering face piece 3 (FFP3) respirators for FRSMs. Results: Whilst using FRSMs, HCWs working on red wards faced an approximately 31-fold (and at least fivefold) increased risk of direct, ward-based infection. Conversely, after changing to FFP3 respirators, this risk was significantly reduced (52-100% protection). Conclusions: FFP3 respirators may therefore provide more effective protection than FRSMs for HCWs caring for patients with COVID-19, whether or not AGPs are undertaken. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
3. Genomic epidemiology of SARS-CoV-2 in a UK university identifies dynamics of transmission.
- Author
-
Aggarwal D, Warne B, Jahun AS, Hamilton WL, Fieldman T, du Plessis L, Hill V, Blane B, Watkins E, Wright E, Hall G, Ludden C, Myers R, Hosmillo M, Chaudhry Y, Pinckert ML, Georgana I, Izuagbe R, Leek D, Nsonwu O, Hughes GJ, Packer S, Page AJ, Metaxaki M, Fuller S, Weale G, Holgate J, Brown CA, Howes R, McFarlane D, Dougan G, Pybus OG, Angelis D, Maxwell PH, Peacock SJ, Weekes MP, Illingworth C, Harrison EM, Matheson NJ, and Goodfellow IG
- Subjects
- COVID-19 prevention & control, COVID-19 virology, Contact Tracing, Genome, Viral genetics, Genomics, Humans, Phylogeny, RNA, Viral genetics, Risk Factors, SARS-CoV-2 classification, SARS-CoV-2 isolation & purification, Students, United Kingdom epidemiology, COVID-19 epidemiology, COVID-19 transmission, SARS-CoV-2 genetics, Universities statistics & numerical data
- Abstract
Understanding SARS-CoV-2 transmission in higher education settings is important to limit spread between students, and into at-risk populations. In this study, we sequenced 482 SARS-CoV-2 isolates from the University of Cambridge from 5 October to 6 December 2020. We perform a detailed phylogenetic comparison with 972 isolates from the surrounding community, complemented with epidemiological and contact tracing data, to determine transmission dynamics. We observe limited viral introductions into the university; the majority of student cases were linked to a single genetic cluster, likely following social gatherings at a venue outside the university. We identify considerable onward transmission associated with student accommodation and courses; this was effectively contained using local infection control measures and following a national lockdown. Transmission clusters were largely segregated within the university or the community. Our study highlights key determinants of SARS-CoV-2 transmission and effective interventions in a higher education setting that will inform public health policy during pandemics., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
4. Mass testing of university students for covid-19.
- Author
-
Matheson NJ, Warne B, Weekes MP, and Maxwell PH
- Subjects
- COVID-19 epidemiology, Humans, Pandemics, SARS-CoV-2, United Kingdom epidemiology, United States epidemiology, COVID-19 diagnosis, COVID-19 Testing methods, Mass Screening methods, Universities
- Abstract
Competing Interests: Competing interests: We have read and understood BMJ policy on declaration of interests and have no interests to declare. Provenance and peer review: Not commissioned; externally peer reviewed.
- Published
- 2021
- Full Text
- View/download PDF
5. How achievable are COVID-19 clinical trial recruitment targets? A UK observational cohort study and trials registry analysis.
- Author
-
Cunniffe NG, Gunter SJ, Brown M, Burge SW, Coyle C, De Soyza A, Dymond T, Esmail H, Francis DP, Galloway J, Galloway JB, Gkrania-Klotsas E, Greenaway J, Katritsis G, Kanagaratnam P, Knolle MD, Leonard K, McIntyre ZC, Prudon B, Rampling T, Torok ME, Warne B, Yates M, Matheson NJ, Su L, Villar S, Stewart GD, and Toshner M
- Subjects
- Betacoronavirus isolation & purification, COVID-19, Eligibility Determination, Female, Health Services Accessibility statistics & numerical data, Hospitalization statistics & numerical data, Humans, Male, Middle Aged, Prospective Studies, Registries statistics & numerical data, SARS-CoV-2, United Kingdom, Biomedical Research organization & administration, Biomedical Research statistics & numerical data, Coronavirus Infections epidemiology, Coronavirus Infections therapy, Pandemics, Patient Selection, Pneumonia, Viral epidemiology, Pneumonia, Viral therapy, Randomized Controlled Trials as Topic methods, Randomized Controlled Trials as Topic statistics & numerical data
- Abstract
Objectives: To analyse enrolment to interventional trials during the first wave of the COVID-19 pandemic in England and describe the barriers to successful recruitment in the circumstance of a further wave or future pandemics., Design: We analysed registered interventional COVID-19 trial data and concurrently did a prospective observational study of hospitalised patients with COVID-19 who were being assessed for eligibility to one of the RECOVERY, C19-ACS or SIMPLE trials., Setting: Interventional COVID-19 trial data were analysed from the clinicaltrials.gov and International Standard Randomized Controlled Trial Number databases on 12 July 2020. The patient cohort was taken from five centres in a respiratory National Institute for Health Research network. Population and modelling data were taken from published reports from the UK government and Medical Research Council Biostatistics Unit., Participants: 2082 consecutive admitted patients with laboratory-confirmed SARS-CoV-2 infection from 27 March 2020 were included., Main Outcome Measures: Proportions enrolled, and reasons for exclusion from the aforementioned trials. Comparisons of trial recruitment targets with estimated feasible recruitment numbers., Results: Analysis of trial registration data for COVID-19 treatment studies enrolling in England showed that by 12 July 2020, 29 142 participants were needed. In the observational study, 430 (20.7%) proceeded to randomisation. 82 (3.9%) declined participation, 699 (33.6%) were excluded on clinical grounds, 363 (17.4%) were medically fit for discharge and 153 (7.3%) were receiving palliative care. With 111 037 people hospitalised with COVID-19 in England by 12 July 2020, we determine that 22 985 people were potentially suitable for trial enrolment. We estimate a UK hospitalisation rate of 2.38%, and that another 1.25 million infections would be required to meet recruitment targets of ongoing trials., Conclusions: Feasible recruitment rates, study design and proliferation of trials can limit the number, and size, that will successfully complete recruitment. We consider that fewer, more appropriately designed trials, prioritising cooperation between centres would maximise productivity in a further wave., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ.)
- Published
- 2020
- Full Text
- View/download PDF
6. Screening of healthcare workers for SARS-CoV-2 highlights the role of asymptomatic carriage in COVID-19 transmission.
- Author
-
Rivett L, Sridhar S, Sparkes D, Routledge M, Jones NK, Forrest S, Young J, Pereira-Dias J, Hamilton WL, Ferris M, Torok ME, Meredith L, Curran MD, Fuller S, Chaudhry A, Shaw A, Samworth RJ, Bradley JR, Dougan G, Smith KG, Lehner PJ, Matheson NJ, Wright G, Goodfellow IG, Baker S, and Weekes MP
- Subjects
- Betacoronavirus physiology, COVID-19, COVID-19 Testing, COVID-19 Vaccines, Coronavirus Infections diagnosis, Coronavirus Infections epidemiology, Coronavirus Infections transmission, Female, Humans, Infection Control, Male, Pandemics, Pneumonia, Viral diagnosis, Pneumonia, Viral epidemiology, Pneumonia, Viral transmission, Real-Time Polymerase Chain Reaction, SARS-CoV-2, United Kingdom epidemiology, Asymptomatic Infections, Clinical Laboratory Techniques, Health Personnel
- Abstract
Significant differences exist in the availability of healthcare worker (HCW) SARS-CoV-2 testing between countries, and existing programmes focus on screening symptomatic rather than asymptomatic staff. Over a 3 week period (April 2020), 1032 asymptomatic HCWs were screened for SARS-CoV-2 in a large UK teaching hospital. Symptomatic staff and symptomatic household contacts were additionally tested. Real-time RT-PCR was used to detect viral RNA from a throat+nose self-swab. 3% of HCWs in the asymptomatic screening group tested positive for SARS-CoV-2. 17/30 (57%) were truly asymptomatic/pauci-symptomatic. 12/30 (40%) had experienced symptoms compatible with coronavirus disease 2019 (COVID-19)>7 days prior to testing, most self-isolating, returning well. Clusters of HCW infection were discovered on two independent wards. Viral genome sequencing showed that the majority of HCWs had the dominant lineage B∙1. Our data demonstrates the utility of comprehensive screening of HCWs with minimal or no symptoms. This approach will be critical for protecting patients and hospital staff., Competing Interests: LR, SS, DS, MR, NJ, SF, JY, JP, WH, MF, LM, MC, SF, AS, JB, GW No competing interests declared, MT Reports grants from Academy of Medical Sciences and the Health Foundation, non-financial support from National Institute of Health Research, grants from Medical Research Council, grants from Global Challenges Research Fund, personal fees from Wellcome Sanger Institute, personal fees from University of Cambridge, personal fees from Oxford University Press, AC Reports grants from Cambridge Biomedical Research Centre at CUHNFT, RS Reports grants from EPSRC fellowship, GD Reports grants from NIHR, KS, MW Reports grants from Wellcome Trust, PL, IG, SB Reports grants from Wellcome Trust and Addenbrooke's Charitable Trust, NM Reports grants from MRC (UK) and NHS Blood and Transfusion, (© 2020, Rivett et al.)
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.